Dual targeting of FLT-3 and IRAK with dual kinase inhibitors has begun to spark interest in its ability to block innate immune signaling, resulting in the prevention of adaptive resistance of FLT3-ITD AML to FLT3 inhibitors. The gene discussed is IRAK1; the disease is acute myeloid leukemia.